Conversion to belatacept after lung transplantation: Report of 10 cases

ABSTRACT:

Background

Calcineurin inhibitors (CNIs) remain the cornerstone of maintenance immunosuppression (IS) after lung transplantation (LTx), although CNI-related life-threatening toxic effects may occur. Belatacept, a novel immunosuppressant that blocks a T-cell co-stimulation pathway, is a non-nephrotoxic drug indicated as an alternative to CNIs in kidney Tx. In LTx, there are only a few reports of belatacept conversion as a CNI-free or CNI-sparing IS treatment.

Methods

We reviewed a series of 10 LTx recipients with conversion to a CNI-free belatacept IS regimen within the first year post-LTx (n = 7) or a belatacept/low-dose CNI combination after the first year (n = 3).

Results

Use of belatacept was triggered by severe renal failure in 9 patients and under-IS with pr

SUBMITTER: Brugiere O 

PROVIDER: S-EPMC10016650 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature